Skip to main content
Chimeric Therapeutics Limited (ASX:CHM)
Australia flag Australia · Delayed Price · Currency is AUD
0.0050
0.00 (0.00%)
Apr 24, 2025, 3:06 PM AEST

Chimeric Therapeutics Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20
Other Revenue
2.047.464.512.62--
Revenue
2.047.464.512.62--
Revenue Growth (YoY)
-83.63%65.52%72.16%---
Gross Profit
2.047.464.512.62--
Selling, General & Admin
8.11911.737.98.970.15
Research & Development
10.9711.1514.436.123.78-
Operating Expenses
19.7220.7229.4917.1914.850.15
Operating Income
-17.68-13.26-24.98-14.57-14.85-0.15
Interest Expense
-0.09-0.33-0.77-0.64-0.01-
Interest & Investment Income
0.10.120.030.010-
Currency Exchange Gain (Loss)
0.060.06-0.09-0.53-0.26-
Other Non Operating Income (Expenses)
----0-
EBT Excluding Unusual Items
-17.61-13.42-25.82-15.73-15.11-0.15
Gain (Loss) on Sale of Assets
-0-0-0-0--
Other Unusual Items
-0.9----
Pretax Income
-17.61-12.52-25.82-15.73-15.11-0.15
Income Tax Expense
0.220.010.090.16--
Net Income
-17.83-12.53-25.92-15.9-15.11-0.15
Net Income to Common
-17.83-12.53-25.92-15.9-15.11-0.15
Shares Outstanding (Basic)
919696433360182-
Shares Outstanding (Diluted)
919696433360182-
Shares Change (YoY)
84.50%60.57%20.37%97.88%--
EPS (Basic)
-0.02-0.02-0.06-0.04-0.08-
EPS (Diluted)
-0.02-0.02-0.06-0.04-0.08-
Free Cash Flow
-5.51-7.54-16.31-13.17-8.85-0.08
Free Cash Flow Per Share
-0.01-0.01-0.04-0.04-0.05-
Gross Margin
100.00%100.00%100.00%100.00%--
Operating Margin
-866.08%-177.82%-554.44%-556.82%--
Profit Margin
-873.54%-168.01%-575.20%-607.48%--
Free Cash Flow Margin
-269.73%-101.07%-361.89%-503.04%--
EBITDA
-16.6-12.18-24.02-13.62-14-
EBITDA Margin
--163.31%----
D&A For EBITDA
1.081.080.970.950.85-
EBIT
-17.68-13.26-24.98-14.57-14.85-0.15
EBIT Margin
--177.82%----
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.